Overview

Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia

Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to compare the effects of tablet treatment, circadian and combined circadian and ultradian subcutaneous hydrocortisone infusion on steroid metabolism and tissue responses to therapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Haukeland University Hospital
Treatments:
Cortisol succinate
Epinephrine
Epinephryl borate
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Racepinephrine